C19orf63 Inhibitors
C19orf63 inhibitors encompass a variety of compounds that indirectly decrease the functional activity of C19orf63 by targeting specific cellular pathways or processes. These inhibitors do not directly bind to or interact with C19orf63, but instead, create cellular conditions that are unfavorable for its activity. Brefeldin A and Monensin perturb protein trafficking and ER-to-Golgi transport, which can sequester C19orf63 in the ER, precluding its proper processing and maturation. Tunicamycin, Thapsigargin, and Cyclopiazonic Acid disrupt protein folding and calcium homeostasis in the ER, which are crucial for the function of many ER-resident proteins, including potentially C19orf63. These disruptions can lead to misfolding, aggregation, and eventual degradation of C19orf63.
Rapamycin, Salubrinal, and MG132 influence protein synthesis and degradation pathways, such as the mTOR pathway and the proteasome, which can result in decreased levels of C19orf63 through reduced synthesis or increased degradation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which impairs protein trafficking and secretion. C19orf63, a protein localized in the endoplasmic reticulum, may rely on intact trafficking pathways for its function or localization, so disruption by Brefeldin A would indirectly inhibit C19orf63 by trapping it in the ER. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that alters intracellular pH and ion concentrations, disrupting lysosomal function and Golgi apparatus trafficking. By perturbing the secretory pathway, C19orf63's function could be indirectly inhibited due to the inability to undergo proper folding or trafficking. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which is critical for the folding and stability of many proteins. If C19orf63 undergoes glycosylation, inhibition by Tunicamycin would lead to misfolding and degradation, decreasing its functional activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a potent inhibitor of the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), leading to depletion of ER calcium stores. As a protein associated with the ER, C19orf63 may require calcium for its function, and depletion by Thapsigargin could inhibit its activity. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic acid is another SERCA inhibitor that depletes ER calcium stores. By a similar mechanism to Thapsigargin, it would indirectly inhibit C19orf63's activity if calcium is essential for its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in protein synthesis and autophagy. Inhibition of mTOR can decrease protein synthesis rates, potentially reducing the levels of C19orf63 if it has a rapid turnover, leading to functional inhibition. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal selectively inhibits phosphatases that dephosphorylate eukaryotic translation initiation factor 2 alpha (eIF2α), leading to reduced global protein synthesis. Lower synthesis rates can indirectly inhibit the function of C19orf63 by reducing its expression levels. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Prolonged inhibition of the proteasome could lead to ER stress and the unfolded protein response (UPR), potentially downregulating C19orf63 as part of the cellular response to mitigate stress. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises the pH in lysosomes, impairing their function and affecting the degradation and recycling of cellular components. This can lead to a buildup of proteins destined for degradation, including possibly C19orf63, indirectly inhibiting its function. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C intercalates into DNA, forming crosslinks and leading to DNA damage responses. Such stress responses can alter the expression of many proteins, potentially including C19orf63, leading to decreased function. | ||||||